<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9908">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01893905</url>
  </required_header>
  <id_info>
    <org_study_id>TM-CS+SG /301</org_study_id>
    <secondary_id>2013-000444-26</secondary_id>
    <nct_id>NCT01893905</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of a New Formulation of Chondroitin Sulfate and Glucosamine Sulfate to Treat Knee Osteoarthritis</brief_title>
  <official_title>Phase III Clinical Trial to Evaluate the Efficacy and Safety of Chondroitin Sulfate and Glucosamine Sulfate in Combination Versus Placebo in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tedec-Meiji Farma, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tedec-Meiji Farma, S.A.</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to assess the efficacy of a new formulation containing chondroitin
      sulfate and glucosamine sulfate (CS+GS) compared with placebo in patients with primary
      osteoarthritis of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduction of pain using VAS</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>OMERACT-OARSI responder criteria</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Index (pain, stiffness and function)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator global assessment</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of rescue medication</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events recording</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>CS+SG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chondroitin sulfate + glucosamine sulfate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chondroitin sulfate + glucosamine sulfate</intervention_name>
    <arm_group_label>CS+SG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient &gt;= 45 years .

          -  Primary OA of the knee according to ACR criteria.

          -  OA radiological grade II-III according to Kellgren and Lawrence.

          -  Patients with moderate-severe pain.

        Exclusion Criteria:

          -  Patients with clinical significant trauma or surgery in the target knee.

          -  Concurrent arthritic disease (antecedents and/or current signs) that could confound
             or interfere with the evaluation of pain efficacy such as chondrocalcinosis, Paget's
             disease of the ipsilateral limb to the target knee, rheumatoid arthritis, aseptic
             osteonecrosis, gout, septic arthritis, ochronosis, acromegaly, haemochromatosis,
             Wilson's disease, osteochondromatosis, seronegative spondyloarthropathy, mixed
             connective tissue disease, collagen vascular disease, psoriasis, inflammatory bowel
             disease or fibromyalgia.

          -  Pain in other parts of the body greater than the knee pain that could interfere with
             the evaluation.

          -  Subjects with any active acute or chronic infections requiring antimicrobial therapy,
             or serious viral (e.g., hepatitis, herpes zoster, HIV positivity) or fungal
             infections.

          -  Clinical diagnosis established of uncontrolled diabetes mellitus.

          -  Patients with asthma.

          -  History of hypersensitivity to the active drugs or any excipients of the
             formulations.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FJ Blanco, Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Universitario La Coru√±a</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pilar Coronel, Ph. D.</last_name>
    <phone>+34 918870980</phone>
    <email>p.coronel@tedecmeiji.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Several study sites</name>
      <address>
        <city>(multicentric Study)</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 2, 2013</lastchanged_date>
  <firstreceived_date>July 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
